Serum fatty acids profile and association with early-onset coronary artery disease

Chao Xuan, Qing-Wu Tian, Hui Li, Jun-Jie Guo, Guo-Wei He and Li-Min Lun

Abstract

Background: Fatty acids (FAs) play crucial roles in modulating and preventing diseases in humans, including early-onset coronary artery disease (EOCAD). In this study, we aimed to provide a profile of FAs in the serum of EOCAD patients and identify potential EOCAD-associated FAs.

Methods: In the first stage, we analyzed the FAs profiles in pooled samples of patients with EOCAD using gas chromatography-mass spectrometry. In the second stage, the serum levels of the candidate FAs were validated in EOCAD patients.

Results: A total of 128 EOCAD patients and 64 controls were included in the study. Forty-nine serum FAs were quantified in pooled samples; three ω-3 FAs were identified to be associated with EOCAD. Moreover, results from the validation stage indicated that serum levels of docosahexaenoic acid (DHA) were significantly lower in EOCAD patients (55.43 ± 33.86 µg/ml) and myocardial infarction (MI) patients (47.49 ± 28.44 µg/ml) than those in the controls (70.65 ± 43.56 µg/ml). Multivariate regression analysis revealed that elevated serum DHA level was an independent protective factor for EOCAD [odds ratio (OR) = 0.8917, 95% confidence interval (CI): 0.879–0.957] and MI [OR = 0.835, 95% CI: 0.799–0.862]. Decreased serum levels of docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA) were observed in the early-onset MI group.

Conclusion: The study provided the serum FAs profile of EOCAD and confirmed that the decrease in serum levels of DHA, DPA, and EPA was associated with EOCAD. These findings might contribute to understanding the cardiovascular effects of FAs, particularly the protective effects of ω-3 polyunsaturated FAs.

Keywords: early-onset coronary artery disease, fatty acids, docosahexaenoic acid, docosapentaenoic acid, eicosapentaenoic acid

Received: 3 February 2021; revised manuscript accepted: 21 June 2021.

Correspondence to:
Chao Xuan
Li-Min Lun
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, No.1677, Wutai Mountain Road, Qingdao (West Coast), 266500, China
bio-x.c8@hotmail.com; lunlmqd@163.com
Qing-Wu Tian, Hui Li
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China
Jun-Jie Guo
Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China
Guo-Wei He
Center for Basic Medical Research & Department of Cardiovascular Surgery, TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Introduction

Cardiovascular disease (CVD) continues to be one of the major contributors to morbidity and mortality worldwide. The complex etiology of CVD encompasses a complicated interplay between genetic predisposition and environmental factors. The association between fatty acids (FAs) and CVD, particularly coronary artery disease (CAD), has been well documented.1–3

FAs, the building blocks of lipids, are carboxylic acids with long aliphatic chains and they represent the predominant source of cellular energy. Depending on the length of the aliphatic chain, FAs are classified as short-chain FAs (aliphatic tails of up to seven carbons), medium-chain FAs (aliphatic tails of 6–12 carbons), long-chain FAs (aliphatic tails of 13–21 carbons), and very long-chain FAs (aliphatic tails of 22 carbons or more; >C22). As well, based on the presence of the carbon–carbon double bonds (–CH=CH–) in the hydrocarbon chain, FAs can be either saturated FAs (SFAs; having only single bonds) or unsaturated FAs (SFAs; having only single bonds) or unsaturated FAs (having double bonds). FAs are essential for diverse biological functions, including lipid metabolism, modulation of the immune system, and lipid signaling.
system, endothelial function, platelet aggregation, and redox status. An alteration in these functions can result in several lipid dysregulation-related diseases, including CAD. FA plays a crucial dual role in the occurrence of CAD. Generally, SFA is known to contribute to the risk of CAD, whereas polyunsaturated FA (PUFA) protects against CVD and significantly reduces the risk of CAD. Recently, increasing epidemiological evidence also indicates that trans-fatty acid, unsaturated FAs with at least one non-conjugated double bond in the trans configuration, can significantly increase the risk of cardiovascular events. Among PUFAs, omega-3 FAs (ω-3 FAs) have gained increasing attention owing to their potential in preventing the development and progression of many disorders, including neurodegenerative, neuropsychiatric, and inflammatory diseases. Alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) are the most represented ω-3 FAs. However, the association between these ω-3 FAs and CVD remains controversial.

CAD predominantly affects the elderly; however, the prevalence of CAD in the young is increasing with changing lifestyles. CAD that occurs in individuals less than 50 years of age is defined as early-onset coronary artery disease (EOCAD). Several etiological factors, including family history, lipid metabolism, gender, and environmental risk factors, have been associated with EOCAD. Furthermore, the long-term prognosis of patients with EOCAD remains poor. Thus, it is imperative to recognize risk factors for the early diagnosis and screening of EOCAD. In this study, we quantitatively identified 49 FAs in the serum of patients with EOCAD and in normal healthy controls using gas chromatography-mass spectrometry (GC-MS). Furthermore, the serum levels of the potential candidate FAs were validated in patients with EOCAD.

**Material and methods**

**Subjects**

In this hospital-based retrospective case–control study, all patients attending the CAD clinic at the Affiliated Hospital of Qingdao University between January 2019 and May 2020 were recruited. A total of 128 patients with CAD were included in the study. Eligible patients fulfilled the following criteria: (1) were less than 50 years of age; (2) met the diagnostic criteria for CAD after being clinically examined using coronary angiography; (3) clinical diagnosis of CAD was based on the presence of at least 50% stenosis in one or more of the major coronary arteries in coronary angiography, combined with the clinical symptoms of angina, changes in cardiac troponin levels, or and electrocardiographic changes. Exclusion criteria were patients with liver diseases, kidney diseases, tumors, and other serious illnesses that may interfere with the study results. All patients were divided into two groups depending on the presence or absence of myocardial infarction (MI): CAD without MI group (n = 64) and MI group (n = 64). Moreover, 64 age- and sex-matched individuals with no history of CVD and no signs or symptoms of cardiovascular events, determined using electrocardiography, were included as healthy controls. The control subjects were volunteers recruited from the Health Management Center with a similar geographical background. The study was conducted in accordance with the ethical standards laid down in the 1975 Declaration of Helsinki. The study protocols were approved by the research ethics committee of the Affiliated Hospital of Qingdao University (QYFYWZLL26377). Written informed consent was obtained from all participants.

**Sample preparation**

Blood samples were collected after overnight fasting of at least 8 h on the morning after admission. Blood was drawn into BD® anticoagulant-free vacuum blood collection tubes. The samples were then allowed to stand at 4°C for 0.5 h and centrifuged at 3500 rev/min for 10 min to obtain serum samples. All samples were frozen at −80°C until further analysis.

**Biochemical measurements**

Serum fasting blood glucose (FBG), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), serum creatinine (Scr), and lipoprotein(a) (Lp(a)) levels were determined using an automatic biochemistry analyzer (Hitachi HCP-7600, Hitachi, Japan).

**Metabolites extraction**

Serum samples (50 μl) were transferred into a 1.5-ml tube and extracted with 430 μl of extraction
solution (V<sub>isopropanol</sub>:V<sub>n-hexane</sub> = 2:3); 20 μl of internal standard solution (1 mg/l in n-hexane) were added to the sample, vortexed (30 s), and then sonicated (5 min). Tubes were centrifuged (12,000g, 15 min) and the supernatant was collected into a fresh 1.5-ml tube and blow-dried with nitrogen. Next, 200 μl methanol and 100 μl (trimethylsilyl) diazomethane was added to the pellet, vortexed (10 s), and allowed to stand at room temperature for 15 min and blow-dried with nitrogen. Subsequently, the pellet was redissolved in 160 μl of n-hexane, centrifuged (12,000g, 5 min) at 4°C, and the supernatant was collected into a fresh vial for GC-MS analysis.

**GC-MS**

GC-MS was performed using an Agilent 7890B GC system (Agilent Technologies, Santa Clara, CA, USA) equipped with an Agilent 5977B mass spectrometer. The system utilized a DB-FastFAME capillary column. The analyte sample (1 μl) was injected in the split mode (5:1). Helium was used as a carrier gas with a front inlet purge flow rate of 3 ml/min and gas flow rate through the column of 46 psi with constant pressure. After 1 min at 75°C, the oven was heated to 200°C at a rate of 50°C/min (hold time 15 min), then ramped up by 2°C/min to 210°C (hold time 1 min); last, the temperature was raised by 10°C/min to 230°C (hold time 16.5 min). The injection, transfer line, quad, and ion source temperatures were 240°C, 240°C, 230°C, and 150°C, respectively. The electron energy was set to −70 eV in electron impact mode. After a solvent delay of 7 min, data were acquired from the m/z range of 33–400 in the Scan/SIM mode.

**Limit of detection and limit of quantitation**

The calibration standard solution was prepared by stepwise dilution of 2-fold and analyzed using GC-MS. The lower limits of detection were determined based on a signal-to-noise (S/N) ratio of 3, whereas the lower limits of quantitation were established based on an S/N ratio of 10, according to the US Food and Drug Administration guidelines for bioanalytical method validation.

**Experiment protocol**

The study was divided into two stages. In the first stage, 200 μl of serum from each sample was taken and mixed into a sample pool for every eight samples. There were eight sample pools in the CAD (without MI) group, eight sample pools in the MI group, and 16 sample pools in the controls. We performed GC-MS to analyze the levels of 49 serum FAs in different groups of sample pools and to screen for potential differences. In the second stage, we used GC-MS to verify the screened differential FAs in each sample and investigated their association with CAD.

**Statistical analysis**

Statistical analyses were conducted using Statistical Package for Social Sciences SPSS 16.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism Software 8 (GraphPad Software Inc., San Diego, CA, USA). Data are presented as mean ± standard deviation (SD). The Kolmogorov–Smirnov test was used to test the null hypothesis that a set of data comes from a normal distribution. The comparisons of categorical variables were performed using the chi-square test or Fisher exact test. Independent samples t-test or one-way analysis of variance (ANOVA) was used to assess the association between variables. A p-value of < 0.05 was considered statistically significant. Power calculations were used to determine the number of subjects required with 0.90 power at an alpha level of 0.05. Estimates were calculated using power analysis and PASS software (version 15.0, NCSS, LLC).

**Results**

**Characteristics of participants**

We included 64 CAD patients (mean age 43.27 ± 4.26 years) and 128 healthy controls (mean age 43.56 ± 4.78 years) in this study. No significant differences were observed in gender, age, body mass index (BMI), hypertension, diabetes, alcohol consumption, TC, HDL-C, LDL-C, and SCr between EOCAD patients and healthy controls. However, FBG, TG, and Lp(a) levels were found to be significantly elevated in patients with EOCAD compared with the controls. As well, patients with EOCAD had a higher smoking rate compared with controls. In the group of patients with EOCAD, 64 were diagnosed with MI. The clinical characteristics of all study subjects are summarized in Table 1.
Profiling of FAs

In the first stage, 49 FAs were quantified using GC-MS. The details of the targeted FAs are presented in Table 2. Among the 49 FAs, significant differences in serum levels of DHA ($p = 0.007$), docosapentaenoic acid (DPA; $p = 0.030$), and EPA ($p = 0.037$) were observed between EOCAD patients and control groups (one-way ANOVA).

Serum DHA levels in the control sample pool ($66.40 \pm 15.48 \mu g/ml$, $n = 8$) group were significantly higher than those in the CAD (without MI) samples pool group ($52.50 \pm 12.21 \mu g/ml$, $n = 8$, $p = 0.028$) and MI samples pool group ($45.85 \pm 5.39 \mu g/ml$, $n = 8$, $p = 0.002$; Figure 1(a)). Serum DPA levels in the MI samples pool group ($8.56 \pm 1.27 \mu g/ml$, $n = 8$) were significantly lower than that of the control samples pool group ($12.09 \pm 3.53 \mu g/ml$, $n = 8$, $p = 0.010$; Figure 1(b)). Similarly, serum EPA levels in the MI samples pools group ($7.72 \pm 1.20 \mu g/ml$, $n = 8$) were also significantly lower than those in the control samples pool group ($11.73 \pm 4.02 \mu g/ml$, $n = 8$, $p = 0.011$; Figure 1(c)). DHA, DPA, and EPA were subsequently selected to be candidate FAs for validation in the next stage.

Validation of the candidate FAs

In the validation stage, the candidate FAs were validated and GC-MS was used to quantify the serum levels of DHA, DPA, and EPA in patients

---

**Table 1.** Demographic and clinical characteristics of patients with EOCAD and controls.

| Variable                          | EOCAD $n = 128$ | Control $n = 64$ | $p$-value |
|-----------------------------------|-----------------|------------------|-----------|
| Gender, male, n (%)               | 128 (98.44)     | 64 (98.44)       | 1.000     |
| Age, years*                       | 43.27 ± 4.26    | 43.56 ± 4.78     | 0.670     |
| BMI, kg/m²*                       | 26.68 ± 5.43    | 25.98 ± 5.98     | 0.417     |
| Hypertension, n (%)               | 32 (25.00)      | 26 (20.31)       | 0.456     |
| Diabetes, n (%)                   | 26 (20.31)      | 18 (14.06)       | 0.246     |
| Smoking, n (%)                    | 68 (53.13)      | 42 (32.81)       | 0.002     |
| Alcohol consumption, n (%)        | 70 (54.69)      | 62 (48.44)       | 0.381     |
| FBG, mmol/l*                      | 6.08 ± 3.22     | 5.02 ± 2.59      | 0.023     |
| TG, mmol/l*                       | 2.20 ± 1.92     | 1.65 ± 1.46      | 0.045     |
| TC, mmol/l*                       | 5.02 ± 1.59     | 4.84 ± 1.45      | 0.448     |
| HDL-C, mmol/l*                    | 1.09 ± 0.38     | 1.18 ± 0.45      | 0.148     |
| LDL-C, mmol/l*                    | 2.77 ± 1.23     | 2.55 ± 1.13      | 0.232     |
| Lp(a), mmol/l*                    | 299.27 ± 287.65 | 215.60 ± 218.56 | 0.042     |
| SCr, μmol/l*                      | 74.56 ± 20.22   | 75.28 ± 22.17    | 0.822     |
| Myocardial infarction, n (%)      | 64 (50.00)      | –                | –         |

*Categorical variables are expressed as percentages. The $p$-value of the categorical variables was calculated using the $\chi^2$ test.

*Continuous variables are expressed as mean ± SD. The $p$-value of the continuous variables was calculated using the unpaired $t$-test.

BMI, body mass index; EOCAD, early-onset coronary artery disease; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); SCr, serum creatinine; TC, total cholesterol; TG, triglyceride.
Table 2. Serum quantitative analysis of 49 fatty acids.

| Fatty acids                  | Control (µg/ml) | CAD (without MI) (µg/ml) | MI (µg/ml) | p*   |
|------------------------------|-----------------|--------------------------|------------|------|
| Octanoic acid                | 0.14 ± 0.05     | 0.21 ± 0.13              | 0.19 ± 0.09 | 0.262|
| Decanoic acid                | 0.47 ± 0.16     | 0.42 ± 0.17              | 0.41 ± 0.08 | 0.706|
| Undecanoic acid              | 0.09 ± 0.02     | 0.08 ± 0.01              | 0.10 ± 0.02 | 0.331|
| Lauric acid                  | 0.75 ± 0.22     | 0.79 ± 0.26              | 0.53 ± 0.20 | 0.081|
| Tridecylic acid              | 0.16 ± 0.01     | 0.16 ± 0.01              | 0.15 ± 0.01 | 0.800|
| Myristic acid                | 15.74 ± 5.85    | 16.10 ± 4.07             | 11.99 ± 3.02 | 0.150|
| trans-9-tetradecenoic acid   | 0.12 ± 0.07     | 0.08 ± 0.04              | 0.11 ± 0.04 | 0.370|
| cis-9-myristoleic acid       | 0.4 ± 0.22      | 0.57 ± 0.19              | 0.34 ± 0.19 | 0.089|
| Pentadecanoic acid           | 2.63 ± 0.52     | 2.63 ± 0.52              | 2.25 ± 0.38 | 0.209|
| trans-10-pentadecenoic acid  | 0.05 ± 0.02     | 0.07 ± 0.01              | 0.06 ± 0.02 | 0.087|
| cis-10-Pentadecenoic acid    | 0.42 ± 0.12     | 0.40 ± 0.10              | 0.36 ± 0.09 | 0.486|
| Palmitic acid                | 510.00 ± 105.99 | 510.12 ± 123.88          | 477.67 ± 57.49 | 0.758|
| trans-9-palmitelaidic acid   | 5.69 ± 5.85     | 6.51 ± 5.61              | 8.85 ± 1.32 | 0.402|
| cis-9-palmitoleic acid       | 29.57 ± 11.07   | 32.95 ± 9.22             | 26.24 ± 4.33 | 0.323|
| Heptadecanoic acid           | 5.76 ± 1.20     | 5.48 ± 1.19              | 4.81 ± 0.55 | 0.188|
| trans-10-heptadecenoic acid  | 0.92 ± 0.27     | 0.58 ± 0.36              | 0.89 ± 0.27 | 0.068|
| cis-10-heptadecenoic acid    | 2.26 ± 0.69     | 2.28 ± 0.51              | 1.94 ± 0.28 | 0.373|
| Stearic acid                 | 199.17 ± 42.05  | 177.69 ± 51.92           | 160.70 ± 15.10 | 0.174|
| trans-6-octadecenoic acid    | 1.66 ± 0.50     | 1.62 ± 0.28              | 1.25 ± 0.43 | 0.112|
| trans-9-elaidic acid         | 0.95 ± 0.55     | 0.79 ± 0.26              | 0.85 ± 0.22 | 0.694|
| trans-11-octadecenoic acid   | 0.71 ± 0.30     | 0.73 ± 0.25              | 0.91 ± 0.61 | 0.589|
| cis-6-octadecenoic acid      | 0.72 ± 0.26     | 0.63 ± 0.15              | 0.61 ± 0.14 | 0.492|
| cis-9-octadecenoic acid      | 728.35 ± 149.98 | 781.22 ± 217.97          | 707.36 ± 91.66 | 0.648|
| cis-11-octadecenoic acid     | 38.85 ± 10.32   | 38.04 ± 10.71            | 36.57 ± 4.24 | 0.875|
| trans,trans-9,12-linoleaidic acid | 0.53 ± 0.18 | 0.41 ± 0.04              | 0.41 ± 0.05 | 0.072|
| cis,cis-9,12-linoleic acid   | 605.90 ± 97.61  | 605.29 ± 187.53          | 530.76 ± 41.32 | 0.397|
| trans-nonadecenoic acid      | 3.15 ± 1.84     | 4.11 ± 2.32              | 2.29 ± 1.01 | 0.157|
| cis,cis,cis-6,9,12-linolenic acid | 5.68 ± 1.6 | 6.54 ± 1.97              | 5.45 ± 1.30 | 0.393|

(Continued)
with CAD (without MI), patients with MI, and control samples one by one. The results of multivariate analysis are shown in Table 3.

The serum levels of DHA in CAD (without MI) patients (55.43 ± 33.86 µg/ml, n=64, p=0.029) and in MI patients (47.49 ± 28.44 µg/ml, n=64, p<0.001) were significantly lower than those in healthy controls (70.65 ± 43.56 µg/ml, n=64; Figure 2). After adjusting for age, BMI, hypertension, diabetes, smoking status, alcohol status, FBG, TG, TC, SCr, HDL-C, LDL-C, and Lp(a) in the logistics regression analysis, DHA was found to be significantly associated with the occurrence of CAD without MI (odds ratio (OR) = 0.8917, 95% confidence interval (CI): 0.879–0.957, p<0.001) and MI (OR = 0.835, 95% CI: 0.799–0.862, p<0.001).

| Fatty acids                                      | Control (µg/ml) | CAD (without MI) (µg/ml) | MI (µg/ml) | p*   |
|-------------------------------------------------|-----------------|--------------------------|------------|------|
| cis,cis-9,12,15-linolenic acid                   | 14.88 ± 7.26    | 19.97 ± 8.80             | 13.07 ± 1.84 | 0.125 |
| Arachidic acid                                  | 2.00 ± 0.36     | 1.87 ± 0.67              | 1.45 ± 0.29 | 0.074 |
| trans-11-eicosenoic acid                       | 21.69 ± 15.31   | 18.12 ± 27.57            | 49.28 ± 38.88 | 0.085 |
| cis-11-eicosenoic acid                         | 6.62 ± 1.67     | 6.10 ± 2.95              | 7.88 ± 2.71 | 0.362 |
| cis,cis-11,14-eicosadienoic acid                | 8.69 ± 1.66     | 7.47 ± 2.06              | 7.06 ± 0.61 | 0.119 |
| Heneicosanoic acid                             | 0.18 ± 0.02     | 0.20 ± 0.06              | 0.22 ± 0.05 | 0.339 |
| cis,cis-8,11,14-linolenic acid                  | 27.26 ± 6.74    | 24.54 ± 6.47             | 24.10 ± 3.98 | 0.517 |
| all-cis-5,8,11,14-eicosatetraenoic acid         | 130.75 ± 31.82  | 115.12 ± 30.77           | 102.48 ± 14.81 | 0.135 |
| all-cis-11,14,17-eicosatrienoic acid            | 1.33 ± 0.46     | 1.16 ± 0.37              | 1.08 ± 0.17 | 0.366 |
| Behenic acid                                    | 0.93 ± 0.27     | 0.97 ± 0.65              | 0.69 ± 0.24 | 0.377 |
| all-cis-5,8,11,14,17-eicosapentaenoic acid      | 11.73 ± 4.02    | 10.11 ± 2.75             | 7.72 ± 1.20 | 0.037 |
| trans-13-docosenoic acid                       | 0.31 ± 0.16     | 0.24 ± 0.20              | 0.46 ± 0.31 | 0.168 |
| cis-13-erucic acid                             | 0.57 ± 0.18     | 0.48 ± 0.07              | 0.45 ± 0.04 | 0.115 |
| cis,cis-13,16-docosadienoic acid                | 0.47 ± 0.21     | 0.42 ± 0.14              | 0.43 ± 0.26 | 0.879 |
| Tricosanoic acid                                | 0.36 ± 0.07     | 0.35 ± 0.12              | 0.44 ± 0.14 | 0.259 |
| all-cis-7,10,13,16-docosatetraenoic acid        | 6.35 ± 1.14     | 6.37 ± 1.85              | 6.04 ± 1.16 | 0.874 |
| all-cis-4,7,10,13,16-docosapentaenoic acid      | 4.23 ± 1.02     | 3.68 ± 0.99              | 3.18 ± 0.59 | 0.082 |
| Lignoceric acid                                 | 0.85 ± 0.19     | 0.77 ± 0.38              | 0.64 ± 0.12 | 0.260 |
| all-cis-4,7,10,13,16,19-docosapentaenoic acid   | 12.09 ± 3.53    | 9.8 ± 2.09               | 8.56 ± 1.27 | 0.030 |
| cis-15-nervonic acid                            | 0.32 ± 0.17     | 0.32 ± 0.13              | 0.29 ± 0.08 | 0.848 |
| all-cis-7,10,13,16,19-docosahexaenoic acid      | 66.40 ± 15.48   | 52.50 ± 12.21            | 45.85 ± 5.39 | 0.007 |

*One-way analysis of variance.
CAD, coronary artery disease; MI, myocardial infarction.
The serum DPA level in the control group (14.12 ± 6.88 µg/ml, n = 64) was significantly higher than that in the MI group (9.96 ± 4.23 µg/ml, n = 64, p < 0.001) and in the CAD (without MI) group (11.91 ± 5.36 µg/ml, n = 64, p = 0.045; Figure 3). After adjusting for all covariables, serum DPA level was identified to be an independent protective factor for MI (OR = 0.828, 95% CI: 0.791–0.878, p < 0.001), but not for CAD without MI (OR = 0.958, 95% CI: 0.917–1.098, p = 0.350).

Serum EPA levels in the MI group (8.99 ± 1.76 µg/ml, n = 64) were significantly lower than those in the control group (12.83 ± 4.51 µg/ml, n = 64, p < 0.001). However, the difference was not detected between the control group and the CAD (without MI) group (11.52 ± 3.25 µg/ml, n = 64, p = 0.062; Figure 4). After adjusting for all factors, the increased serum EPA level was found to be an independent protective factor for MI (OR = 0.848, 95% CI: 0.801–0.895, p < 0.001).

Discussion

In the present study, we quantified serum levels of 49 FAs in patients with EOCAD and in healthy controls and identified three FAs that were markedly associated with EOCAD. Results from the validation stage indicated that decreased serum levels of DHA, DPA, and EPA were associated with an increased risk of EOCAD and/or early-onset MI and could be considered independent risk factors for EOCAD.

CAD is a complex multifactorial disease that is influenced by both genetic and environmental
Table 3. Associations between serum DHA, DPA, and EPA levels and the presence of CAD.

| Adjustment models | DHA |  |  |  |  |  |  |  |  |  |  |  |
|-------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|                   | CAD (without MI) OR (95% CI) p | MI OR (95% CI) p | CAD (without MI) OR (95% CI) p | MI OR (95% CI) p | CAD (without MI) OR (95% CI) p | MI OR (95% CI) p | CAD (without MI) OR (95% CI) p | MI OR (95% CI) p | CAD (without MI) OR (95% CI) p | MI OR (95% CI) p | CAD (without MI) OR (95% CI) p | MI OR (95% CI) p |
| Model 1: Crude    |  - 0.029 -  |  - 0.001 -  |  - 0.045 -  |  - <0.001 -  |  - 0.062 -  |  - <0.001 -  |  - 0.029 -  |  - 0.001 -  |  - 0.062 -  |  - <0.001 -  |  - 0.029 -  |  - 0.001 -  |
| Model 2: Adjusting for smoking, FBG, TG, and Lp(a) | 0.920 (0.882–0.961) <0.001 | 0.964 (0.921–1.012) <0.001 | 0.981 (0.946–1.035) <0.001 | 0.977 (0.928–1.026) <0.001 | 0.977 (0.928–1.026) <0.001 | 0.977 (0.928–1.026) <0.001 | 0.828 (0.791–0.878) <0.001 | 0.849 (0.814–0.895) <0.001 | 0.977 (0.928–1.026) <0.001 | 0.977 (0.928–1.026) <0.001 | 0.977 (0.928–1.026) <0.001 | 0.977 (0.928–1.026) <0.001 |
| Model 3: Adjusting for all factors | 0.917 (0.879–0.957) <0.001 | 0.835 (0.799–0.862) <0.001 | 0.958 (0.917–1.010) <0.001 | 0.977 (0.928–1.026) <0.001 | 0.977 (0.928–1.026) <0.001 | 0.977 (0.928–1.026) <0.001 | 0.828 (0.791–0.878) <0.001 | 0.849 (0.814–0.895) <0.001 | 0.977 (0.928–1.026) <0.001 | 0.977 (0.928–1.026) <0.001 | 0.977 (0.928–1.026) <0.001 | 0.977 (0.928–1.026) <0.001 |

CAD, coronary artery disease; CI, confidence interval; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; FBG, fasting blood glucose; Lp(a), lipoprotein(a); MI, myocardial infarction; OR, odds ratio; TG, triglyceride.
factors. Although CAD exhibits a wide spectrum of etiologies, atherosclerosis represents the predominant pathogenic process that causes CAD. Atherosclerosis is a progressive chronic inflammatory process characterized by the accumulation of lipids, fibrous elements, and molecules of inflammation in the walls of the large arteries.\(^{12,13}\) The oxidative modification of LDL is integrally involved in the instability of the atherosclerosis plaque, which triggers a cascade of events leading to the initiation of the atherosclerotic lesion.\(^{14}\) The early lesions of atherosclerosis comprise accumulations of oxidized low-density lipoprotein (LDL) in macrophages to form foam cells, which serve to perpetuate atherosclerotic plaque formation by releasing chemokines and mitogens that recruit more macrophages, promote the accumulation of lipid-rich necrotic debris, and enhance the migration and proliferation of smooth muscle cells into the intima.\(^{15}\) Atherosclerotic plaque narrows the coronary arteries and obstructs blood flow, leading to myocardial ischemia, unstable angina, and stroke. The most common acute clinical manifestation is MI, which is caused by the rupture of atherosclerotic plaques, blocking the distal coronary arteries, and ultimately leading to myocardial necrosis. Results of a meta-regression of randomized clinical trials also demonstrate that regression of atherosclerotic coronary plaque volume may represent a surrogate for myocardial infarction and repeat revascularization.\(^{16}\) The strong association between elevated serum lipid levels and atherosclerosis development has been well-documented.\(^{17}\) FAs are the important components of lipids and are recognized as essential nutrients for the human body. FAs are biologically active molecules with various cellular processes, including cellular signaling pathways, membrane architecture, cell–cell, cell protein interactions, transcriptional and translational modulation, and energy storage.\(^{18}\) Depending on the presence of carbon–carbon double bonds, FAs are classified into SFA, monounsaturated fatty acids (MUFAs), and PUFA.\(^{19}\) SFA does not contain double-bonded carbons. A number of studies in animals have demonstrated that SFAs elevate serum LDL and TC levels by inhibiting the activity of LDL receptors and enhancing apolipoprotein B levels.\(^{20}\) However, different meta-analyses have provided diverse and conflicting results in humans; thus, the relationship between SFA and CVD risk remains controversial.\(^{21}\) In this study, no significant differences were detected in serum SFA levels between patients in the EOCAD group and the healthy control group. MUFA has only one double-bonded carbon and is widely present in various foods and can be completely absorbed by the intestines to perform biological functions. Like SFA, the relationship between MUFA and the risk of CVD remains controversial.\(^{22}\) Yu and co-workers observed that MUFA significantly decreases serum TC and LDL-C and increases serum HDL-C levels.\(^{23}\) However, Schwingshackl et al.\(^ {24}\) conducted a meta-analysis of randomized control trials with a duration of at least 6 months and revealed that high MUFA diet and low MUFA diet had no significant effect on body weight, waist circumference, LDL, HDL, TG, and TC. As well, in several studies where MUFA content exceeds 20% of total energy consumption, no detrimental changes in cardiovascular-related biomarkers have been observed.\(^ {25,26}\) Consistent with these findings, the present study also revealed no associations between serum MUFA levels and EOCAD. PUFA contains more than one unsaturated carbon in its backbone. PUFAs

![Figure 4. Serum EPA levels in patients with EOCAD and healthy controls. Serum EPA levels in patients with early-onset MI (8.99 ± 1.76 µg/ml, n = 64) were significantly lower than those in patients with CAD (without MI) (11.52 ± 3.25 µg/ml, n = 64, p < 0.001) and controls (12.83 ± 4.51 µg/ml, n = 64, p < 0.001). There were no significant differences in serum EPA levels between the control and CAD (without MI) patients (p = 0.062). EOCAD, early-onset coronary artery disease; CAD, coronary artery disease; EPA, eicosapentaenoic acid; MI, myocardial infarction.](journals.sagepub.com/home/taj)
are divided into two families, ω-3 and ω-6. Among them, the relationship between ω-3 PUFAs and the risk of CVD has been extensively studied. There are three main types of ω-3 FAs, including EPA, DHA, and ALA. EPA and DHA are commonly found in marine oils, and ALA is found mainly in plant oils. ALA can be obtained only from dietary sources as the enzymes needed to synthesize ALA are lacking in the human body. A study has indicated that approximately 8–20% of ALA can be converted to EPA, and approximately 0.5–9% of ALA is converted to DHA in humans. Observational and retrospective studies have yielded almost the same conclusion, that the intake of ω-3 can significantly reduce the incidence of cardiovascular events. 27

The Diet and Reinfarction Trial (DART) study revealed that eating two to three portions of fatty fish weekly reduced the 2-year all-cause mortality rate among patients with MI by nearly 30%.28 The GISSI-Prevenzione study also confirmed that the oral administration of ω-3 PUFAs in patients with MI could significantly reduce all-cause mortality and cardiovascular mortality MI.29 It should be noted that apart from TG, there is still no strong reverse relationship between ω-3 and blood lipids (TC, HDL, and LDL). Therefore, the cardioprotective effect of ω-3 PUFAs may not be achieved entirely by regulating blood lipid metabolism. The cardiovascular protective effect of ω-3 PUFAs is due to their actions on the metabolism of lipids, vessels, and platelets, by which they achieve a significant anti-arrhythmic effect, lowered blood pressure, reduced inflammation and improved endothelial dysfunction, increased autonomic vascular tone, and reduced platelet aggregation.30 In the present study, we also detected a significant decrease in DPA, DHA, and EPA in the serum of patients with EOCAD or early-onset MI.

Patients with EOCAD were younger than 50 years, and the etiology may have some differences compared with late-onset CAD. In recent years, numerous biomarkers have already been identified for EOCAD, including genes, proteins, and other biomacromolecules. We previously demonstrated that the MTHFR and ALMSI variants were associated with the risk of EOCAD, and serum levels of asymmetric dimethylarginine, uric acid, and adenosine deaminase were associated with the presence and severity of EOCAD.31–36 Based on serum differential proteomics, our study confirmed an aberrant metabolism of serum lipoproteins (Apo A-I, Apo A-IV, Apo C-I) in EOCAD.37

To the best of our knowledge, only a few studies have analyzed the correlation between EOCAD and serum FAs levels, particularly on FA profiles. Recently, Bittner and co-workers have found that serum DHA levels in control patients were significantly higher than EPA and DPA. However, there is still no strong reverse relationship between DPA, DHA, and EPA. However, the difficulty of purification, the physiological role of DPA is not well understood. Recent reviews have summarized the possible roles of DPA associated with cardiovascular protection, mental health, and cancers. It is generally believed that the protective functions of DHA in the cardiovascular system include anti-inflammatory properties, inhibition of cytokine synthesis, decrease in thrombosis, decrease in plasma lipids, and inhibition of atherosclerosis.42 In this study, we found that serum DHA levels in control patients were significantly higher than EPA and DPA. Besides, the serum levels of DHA were
significantly decreased in patients with EOCAD (including MI); however, the serum levels of DPA and EPA were significantly decreased in patients with early-onset MI. Together, these findings indicate to a certain extent that DHA may be superior to DPA and EPA in conferring cardioprotective effects. We did not detect significant changes in serum ALA levels in patients with EOCAD and these findings were consistent with those of previous studies.

Our study has some limitations. First, this was a retrospective case–control study, and we could not assess the cause and effect of serum FAs levels on the dynamic progression of EOCAD. Second, most study participants were from coastal areas with seawater fish as a major constituent of the diet. Thus, serum PUFA levels may have been affected by their diet. Third, there were only a few female patients with EOCAD in this study. Although there may be differences in serum FAs levels between the genders, subgroup analysis could not be performed. Thus, studies on larger patient cohorts are warranted to further validate the findings of our study.

**Conclusions**
To summarize, this study provides a profile of serum FAs in patients with EOCAD. Notably, 49 serum FAs were initially screened and quantified, and three PUFAs were identified to be associated with the risk of EOCAD. The results also indicated that low levels of DHA were associated with EOCAD and early-onset MI, and low levels of DPA and EPA were associated only with early-onset MI. Collectively, these findings provide insights for future studies on the diverse characteristics of lipid metabolism and the protective effects of ω-3 PUFAs in patients with EOCAD.

**Author contributions**
CX and LML designed the study; HL, QWT, and JJG performed the experiments, CX, HL, and JJG analyzed and interpreted the data; CX wrote the manuscript, GWH reviewed and revised the manuscript; all authors approved the final manuscript.

**Availability of supporting data**
The datasets used and/or analyzed during this current study are available from the corresponding author on reasonable request.

**Conflict of interest statement**
The authors declare that there is no conflict of interest.

**Consent for publication**
Informed consent form for publication was obtained from all authors.

**Ethics statement**
The study was approved by the ethics committee of The Affiliated Hospital of Qingdao University.

**Funding**
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the study was supported by grants from the National Natural Science Foundation of China (no. 81672073, 81800238), China Postdoctoral Science Foundation (no. 2016M590620), and Shandong Medical and Healthy Outstanding Personalities Cultivation Project (no. 3522).

**ORCID iD**
Chao Xuan https://orcid.org/0000-0001-8273-0178

**References**
1. Ghosh A, Gao L, Thakur A, et al. Role of free fatty acids in endothelial dysfunction. *J Biomed Sci* 2017; 24: 50.
2. Lecerf JM. Fatty acids and cardiovascular disease. *Nutr Rev* 2009; 67: 273–283.
3. Baum SJ, Kris-Etherton PM, Willett WC, et al. Fatty acids in cardiovascular health and disease: a comprehensive update. *J Clin Lipidol* 2012; 6: 216–234.
4. Shramko VS, Polonskaya YV, Kashtanova EV, et al. The short overview on the relevance of fatty acids for human cardiovascular disorders. *Biomolecules* 2020; 10: 1127.
5. Mazidi M, Cicero AF, Kengne AP, et al. Association between plasma trans-fatty acid concentrations and measures of glucose homeostasis and cardiovascular risk factors in adults in NHANES 1999-2000. *Angiology* 2018; 69: 630–637.
6. Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis
of 10 trials involving 77 917 individuals. *JAMA Cardiol* 2018; 3: 225–234.

7. Kathiresan S, Voight BF, Purcell S, *et al.* Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nat Genet* 2009; 41: 334–341.

8. Khera AV, Chaffin M, Zekavat SM, *et al.* Whole-genome sequencing to characterize monogenic and polygenic contributions in patients hospitalized with early-onset myocardial infarction. *Circulation* 2019; 139: 1593–1602.

9. Pang J, Poulter EB, Bell DA, *et al.* Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. *J Clin Lipidol* 2015; 9: 703–708.

10. Cipriani V, Mannucci PM, Ardissono D, *et al.* Familial aggregation of early-onset myocardial infarction. *Eur J Intern Med* 2010; 21: 511–515.

11. Cole JH, Miller J 3rd, Sperling LS, *et al.* Long-term follow-up of coronary artery disease presenting in young adults. *J Am Coll Cardiol* 2003; 41: 521–528.

12. Davidson J and Rotondo D. Lipid metabolism: inflammatory-immune responses in atherosclerosis. *Curr Opin Lipidol* 2003; 14: 339–339.

13. van Diepen JA, Berbée JF, Havekes LM, *et al.* Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. *Atherosclerosis* 2013; 228: 306–315.

14. Colles SM, Maxson JM, Carlson SG, *et al.* Oxidized LDL-induced injury and apoptosis in atherosclerosis. Potential roles for oxysterols. *Trends Cardiovasc Med* 2001; 11: 131–138.

15. Maguire EM, Pearce S and Xiao Q. Foam cell formation: a new target for fighting atherosclerosis and cardiovascular disease. *Vascul Pharmacol* 2019; 112: 54–71.

16. Ascenzo F, Agostoni P, Abbate A, *et al.* Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. *Atherosclerosis* 2013; 226: 178–185.

17. Lewis LA, Olmsted F, Page IH, *et al.* Serum lipid levels in normal persons; findings of a cooperative study of lipoproteins and atherosclerosis. *Circulation* 1957; 16: 227–245.

18. Cascio G, Schiera G and Di Liegro I. Dietary fatty acids in metabolic syndrome, diabetes and cardiovascular diseases. *Curr Diabetes Rev* 2012; 8: 2–17.

19. Vissers L, Rijksen J, Boer J, *et al.* Fatty acids from dairy and meat and their association with risk of coronary heart disease. *Eur J Nutr* 2019; 58: 2639–2647.

20. Dietschy JM. Dietary fatty acids and the regulation of plasma low density lipoprotein cholesterol concentrations. *J Nutr* 1998; 128(2 Suppl.): 444S–448S.

21. Siri-Tarino PW, Sun Q, Hu FB, *et al.* Saturated fatty acids and risk of coronary heart disease: modulation by replacement nutrients. *Curr Atheroscler Rep* 2010; 12: 384–390.

22. Schwingshackl L and Hoffmann G. Monounsaturated fatty acids and risk of cardiovascular disease: synopsis of the evidence available from systematic reviews and meta-analyses. *Nutrients* 2012; 4: 1989–2007.

23. Yu S, Derr J, Etherton TD and Kris-Etherton PM. Plasma cholesterol-predictive equations demonstrate that stearic acid is neutral and monounsaturated fatty acids are hypocholesterolemic. *Am J Clin Nutr* 1995; 61: 1129–1139.

24. Schwingshackl L, Strasser B and Hoffmann G. Effects of monounsaturated fatty acids on cardiovascular risk factors: a systematic review and meta-analysis. *Ann Nutr Metab* 2011; 59: 176–186.

25. Brehm BJ, Lattin BL, Summer SS, *et al.* One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. *Diabetes Care* 2009; 32: 215–220.

26. Due A, Larsen TM, Mu H, *et al.* Comparison of 3 ad libitum diets for weight-loss maintenance, risk of cardiovascular disease, and diabetes: a 6-mo randomized, controlled trial. *Am J Clin Nutr* 2008; 88: 1232–1241.

27. Bilato C. n-3 fatty acids and cardiovascular disease: the story is not over yet. *Aging Clin Exp Res* 2013; 25: 357–363.

28. Burr ML, Fehily AM, Gilbert JF, *et al.* Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). *Lancet* 1989; 2: 757–761.

29. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. *Lancet* 1999; 354: 447–455.
30. Oppedisano F, Macri R, Gliozzi M, et al. The anti-inflammatory and antioxidant properties of n-3 PUFAs: their role in cardiovascular protection. Biomedicines 2020; 8: 306.

31. Zhang SY, Xuan C, Wang Y, et al. Association between ALMS 1 variants and early-onset coronary artery disease: a case-control study in Chinese population. Biosci Rep 2020; 40: BSR20193637.

32. Xuan C, Liu ZF, Wang Q, et al. Increased serum concentrations of asymmetric dimethylarginine (ADMA) in patients with early-onset coronary artery disease. Clin Chim Acta 2017; 464: 195–199.

33. Tian TT, Li H, Chen SJ, et al. Serum uric acid as an independent risk factor for the presence and severity of early-onset coronary artery disease: a case-control study. Dis Markers 2018; 2018: 1236837.

34. Xuan C, Tian QW, Li H, et al. Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: a meta-analysis based on 4713 participants. Eur J Prev Cardiol 2016; 23: 502–510.

35. Zhang SY, Xuan C, Zhang XC, et al. Association between MTHFR gene common variants, serum homocysteine, and risk of early-onset coronary artery disease: a case-control study. Biochem Genet 2020; 58: 245–256.

36. Xuan C, Tian QW, Zhang SY, et al. Serum adenosine deaminase activity and coronary artery disease: a retrospective case-control study based on 9929 participants. Ther Adv Chronic Dis 2019; 10: 2040622319891539.

37. Xuan C, Li H, Li LL, et al. Screening and identification of pregnancy zone protein and leucine-rich alpha-2-glycoprotein as potential serum biomarkers for early-onset myocardial infarction using protein profile analysis. Proteomics Clin Appl 2019; 13: e1800079.

38. Bittner DO, Goeller M, Zopf Y, et al. Early-onset coronary atherosclerosis in patients with low levels of omega-3 fatty acids. Eur J Clin Nutr 2020; 74: 651–656.

39. Yagi S, Aihara K, Fukuda D, et al. Reduced ratio of eicosapentaenoic acid and docosahexaenoic acid to arachidonic acid is associated with early onset of acute coronary syndrome. Nutr J 2015; 14: 111.

40. Hite AH, Feinman RD, Guzman GE, et al. In the face of contradictory evidence: report of the Dietary Guidelines for Americans Committee. Nutrition 2010; 26: 915–924.

41. DeSalvo KB, Olson R and Casavale KO. Dietary guidelines for Americans. JAMA 2016; 315: 457–458.

42. Drouin G, Rioux V and Legrand P. The n-3 docosapentaenoic acid (DPA): a new player in the n-3 long chain polyunsaturated fatty acid family. Biochimie 2019; 159: 36–48.